X4 Pharmaceuticals (XFOR) Accounts Payables (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Accounts Payables data on file, last reported at $5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 33.93% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2025 stood at $5.7 million (down 33.93% YoY), and the FY2025 full-year result was $5.7 million, down 33.93% from the prior year.
• Accounts Payables for Q4 2025 stood at $5.7 million, up from $5.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.1 million in Q1 2025 and bottomed at $2.4 million in Q3 2021.
• The 5-year median for Accounts Payables is $5.8 million (2023), against an average of $6.2 million.
• The widest annual swing landed in 2021, when Accounts Payables jumped 147.68%; it then plunged 41.09% in 2025.
• A 5-year view of Accounts Payables shows it stood at $4.3 million in 2021, then jumped by 81.58% to $7.8 million in 2022, then rose by 15.04% to $8.9 million in 2023, then fell by 3.64% to $8.6 million in 2024, then sank by 33.93% to $5.7 million in 2025.
• The last three Accounts Payables figures came in at $5.7 million (Q4 2025), $5.1 million (Q3 2025), and $7.7 million (Q2 2025), per Business Quant data.

Peer Comparison